Bridging the gap

References

• Intelligence LMB. Top 30 Biologics 2010. R&D Pipeline News 2011;
   Google Scholar
• Maggon K. Twenty Best Selling Drugs 2010 2011; Knol Publishing http://knol.google.com/k/krishan-maggon/top-ten-twenty-best-selling-drugs-2010/3fy5eowy8suq3/141
   Google Scholar
• Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs 2009; 1:443 - 452
   PubMed Web of Science ®Google Scholar
• Petering J, McManamny P, Honeyman J. Antibody therapeutics—the evolving patent landscape biotechnology annual review 2011. N Biotechnol 2011; 28:538 - 544
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8:473 - 480
   PubMed Web of Science ®Google Scholar
• Aggarwal S. What's fueling the biotech engine-2009–2010. Nat Biotechnol 2010; 28:1165 - 1171
   PubMed Web of Science ®Google Scholar
• Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010; 28:917 - 924
   PubMed Web of Science ®Google Scholar
• Reichert JM. Metrics for antibody therapeutics development. mAbs 2010; 2:695 - 700
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 497
   PubMed Web of Science ®Google Scholar
• Tjandra JJ, Ramadi L, Mckenzie IFC. Development of Human Antimurine Antibody (Hama) Response in Patients. Immunol Cell Biol 1990; 68:367 - 376
   PubMed Web of Science ®Google Scholar
• Winter G, Milstein C. Man-made antibodies. Nature 1991; 349:293 - 299
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81:6851 - 6855
   PubMed Web of Science ®Google Scholar
• Jones ST, Bendig MM. Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Biotechnology 1991; 9:88 - 89
   PubMed Web of Science ®Google Scholar
• Getts DR, Getts MT, McCarthy DP, Chastain EML, Miller SD. Have we overestimated the benefit of human(ized) antibodies?. mAbs 2010; 2:682 - 694
   PubMed Web of Science ®Google Scholar
• McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348:552 - 554
   PubMed Web of Science ®Google Scholar
• Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581 - 597
   PubMed Web of Science ®Google Scholar
• Bradbury AR, Sidhu S, Dubel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 2011; 29:245 - 254
   PubMed Web of Science ®Google Scholar
• Jones ML, Seldon T, Smede M, Linville A, Chin DY, Barnard R, et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. J Immunol Methods 2010; 354:85 - 90
   PubMed Web of Science ®Google Scholar
• Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006; 1:755
   PubMed Web of Science ®Google Scholar
• Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 2003; 21:163 - 170
   PubMed Web of Science ®Google Scholar
• Kellermann SA, Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotech 2002; 13:593 - 597
   PubMed Web of Science ®Google Scholar
• Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008; 20:450 - 459
   PubMed Web of Science ®Google Scholar
• Jakobovits A, Amad RG, Yang X, RoskoS L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25:1134 - 1143
   PubMed Web of Science ®Google Scholar
• Bradley A. Kymouse Platform to generate highly selective, potent and well-tolerated human antibody-based biopharmaceuticals PEGS Summit 2011 Boston
   Google Scholar
• Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. mAbs 2011; 3:243 - 252
   PubMed Web of Science ®Google Scholar
• Loo L, Robinson MK, Adams GP. Antibody engineering principles and applications. Cancer J 2008; 14:149 - 153
   PubMed Web of Science ®Google Scholar
• Presta L. Antibody engineering for therapeutics. Curr Opin Struct Biol 2003; 13:519 - 525
   PubMed Web of Science ®Google Scholar
• Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22:1393 - 1398
   PubMed Web of Science ®Google Scholar
• Rita Costa A, Elisa Rodrigues M, Henriques M, Azeredo J, Oliveira R. Guidelines to cell engineering for monoclonal antibody production. Eur J Pharm Biopharm 2010; 74:127 - 138
   PubMed Web of Science ®Google Scholar
• Potgieter TI, Cukan M, Drummond JE, Houston-Cummings NR, Jiang Y, Li F, et al. Production of monoclonal antibodies by glycoengineered Pichia pastoris. J Biotechnol 2009; 139:318 - 325
   PubMed Web of Science ®Google Scholar
• Hou JJC, Codamo J, Pilbrough W, Hughes B, Gray PP, Munro TP. New frontiers in cell line development: Challenges for biosimilars. J Chem Technol Biotechnol 2011; 86:895 - 904
   Web of Science ®Google Scholar
• Codamo J, Munro TP, Hughes BS, Song M, Gray PP. Enhanced CHO cell-based transient gene expression with the Epi-CHO expression system. Mol Biotechnol 2011; 48:109 - 115
   PubMed Web of Science ®Google Scholar
• Backliwal G, Hildinger M, Hasija V, Wurm FM. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng 2008; 99:721 - 727
   PubMed Web of Science ®Google Scholar
• Wulhfard S, Tissot S, Bouchet S, Cevey J, De Jesus M, Hacker DL, et al. Mild hypothermia improves transient gene expression yields several fold in Chinese hamster ovary cells. Biotechnol Prog 2008; 24:458 - 465
   PubMed Web of Science ®Google Scholar
• Rajendra Y, Kiseljak D, Baldi L, Hacker DL, Wurm FM. A simple high-yielding process for transient gene expression in CHO cells. J Biotechnol 2011; 153:22 - 26
   PubMed Web of Science ®Google Scholar
• Codamo J, Hou JJC, Hughes BS, Gray PP, Munro TP. Efficient mAb production in CHO cells incorporating PEI-mediated transfection, mild hypothermia and the co-expression of XBP-1. J Chem Technol Biotechnol 2011; 86:923 - 934
   Web of Science ®Google Scholar
• Schimke RT. Gene amplification in cultured animal cells. Cell 1984; 37:705 - 713
   PubMed Web of Science ®Google Scholar
• de la Cruz Edmonds MC, Tellers M, Chan C, Salmon P, Robinson DK, Markusen J. Development of transfection and high-producer screening protocols for the CHOK1SV cell system. Mol Biotechnol 2006; 34:179 - 190
   PubMed Web of Science ®Google Scholar
• Antoniou M, Harland L, Mustoe T, Williams S, Holdstock J, Yague E, et al. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 2003; 82:269 - 279
   Google Scholar
• Zahn-Zabal M, Kobr M, Girod PA, Imhof M, Chatellard P, de Jesus M, et al. Development of stable cell lines for production or regulated expression using matrix attachment regions. J Biotechnol 2001; 87:29 - 42
   PubMed Web of Science ®Google Scholar
• Browne SM, Al-Rubeai M. Selection methods for high-producing mammalian cell lines. Trends Biotechnol 2007; 25:425 - 432
   PubMed Web of Science ®Google Scholar
• Pilbrough W, Munro TP, Gray P. Intraclonal protein expression heterogeneity in recombinant CHO cells. PLoS One 2009; 4:8432
   PubMed Web of Science ®Google Scholar
• Sleiman RJ, Gray PP, McCall MN, Codamo J, Sunstrom NA. Accelerated cell line development using two-color fluorescence activated cell sorting to select highly expressing antibody-producing clones. Biotechnol Bioeng 2008; 99:578 - 587
   PubMed Web of Science ®Google Scholar
• Song M, Raphaelli K, Jones ML, Aliabadi-Zadeh K, Leung KM, Crowley D, et al. Clonal selection of high producing, stably transfected HEK293 cell lines utilizing modified, high-throughput FACS screening. J Chem Technol Biotechnol 2011; 86:935 - 941
   Web of Science ®Google Scholar
• Dietmair S, Nielsen LK, Timmins NE. Engineering a mammalian super producer. J Chem Technol Biotechnol 2011; 86:905 - 914
   Web of Science ®Google Scholar
• Liu PQ, Chan EM, Cost GJ, Zhang L, Wang J, Miller JC, et al. Generation of a triple-gene knockout mammalian cell line using engineered zinc-finger nucleases. Biotechnol Bioeng 2010; 106:97 - 105
   PubMed Web of Science ®Google Scholar
• Muller N, Derouazi M, Van Tilborgh F, Wulhfard S, Hacker DL, Jordan M, et al. Scalable transient gene expression in Chinese hamster ovary cells in instrumented and non-instrumented cultivation systems. Biotechnol Lett 2007; 29:703 - 711
   PubMed Web of Science ®Google Scholar
• Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. mAbs 2010; 2:480 - 499
   PubMed Web of Science ®Google Scholar
• Gagnon P. Monoclonal antibody purification with hydroxyapatite. N Biotechnol 2009; 25:287 - 293
   PubMed Web of Science ®Google Scholar
• Chamberlain P. Preclinical strategies and safety issues in developing therapeutic monoclonal antibodies. N Biotechnol 2011; 28:481
   PubMed Web of Science ®Google Scholar
• Snodin DJ, Ryle PR. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals. BioDrugs 2006; 20:25 - 52
   PubMed Web of Science ®Google Scholar
• Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. mAbs 2009; 1:505 - 516
   PubMed Web of Science ®Google Scholar
• Lynch CM, Grewal IS. Preclinical safety evaluation of monoclonal antibodies. Handb Exp Pharmacol 2008; 19 - 44
   PubMedGoogle Scholar
• Lynch CM, Hart BW, Grewal IS. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. mAbs 2009; 1:2 - 11
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008; 97:2426 - 2447
   PubMed Web of Science ®Google Scholar
• Petsch D, Anspach FB. Endotoxin removal from protein solutions. J Biotechnol 2000; 76:97 - 119
   PubMed Web of Science ®Google Scholar
• Zoon K. FDA. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use 1997;
   Google Scholar
• WHO. WHO Expert Committee on Biological Standardization. Highlights of the 46th meeting, October 1996. Wkly Epidemiol Rec 1997; 141 - 145
   PubMedGoogle Scholar
• Rathore AS. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 2009; 27:546 - 553
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126 - 1136
   PubMed Web of Science ®Google Scholar
• Skerra A, Gebauer M. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13:245 - 255
   PubMed Web of Science ®Google Scholar
• Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaia N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329 - 339
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767 - 774
   PubMed Web of Science ®Google Scholar
• Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010; 10:1011 - 1018
   PubMed Web of Science ®Google Scholar
• Cloonan N, Waddell N, Grimmond SM. The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics. IDrugs 2010; 13:778 - 781
   PubMed Web of Science ®Google Scholar
• Flatman S, Alam I, Gerard J, Mussa N. Process analytics for purification of monoclonal antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848:79 - 87
   PubMed Web of Science ®Google Scholar